United Biomedical Inc Asia (聯亞生技) on Sunday urged the government to give its COVID-19 vaccine candidate, UB-612, a second chance, after its application for emergency use authorization (EUA) was denied last week.
Company founder Wang Chang-yi (王長怡) said that the Food and Drug Administration’s (FDA) standards for granting an EUA were hastily devised and outdated.
In assessing the effectiveness of a vaccine candidate, the FDA only considers the virus neutralizing antibodies — expressed as geometric mean titers (GMTs) — but the reaction of T-cells should also be part of the equation, Wang said.
Photo: CNA
The FDA should compare the effectiveness of the UB-612 vaccine and the AstraZeneca vaccine against the Delta variant of SARS-CoV-2, given that the variant is the most contagious, she said.
“It would be deeply regrettable to deny people access to such a good vaccine because of hastily devised EUA standards,” Wang said.
Despite the setback, the firm remains committed to seeking international approval for its COVID-19 vaccine candidate, she said.
United Biomedical said that it would soon appeal the FDA’s decision not to grant an EUA for the UB-612 vaccine.
The FDA respects the company’s right to appeal, it said, adding that it would review the application and decide whether another meeting of experts would be necessary.
On Monday last week, the FDA said that a majority of the experts had on Sunday voted not to grant the company an EUA.
To be granted an EUA, a vaccine must have a seroconversion rate of more than 50 percent, with GMTs at least equal to two-thirds of the level found in recipients of the AstraZeneca vaccine.
The FDA decided to test the antibody concentrations against people who had been inoculated with the AstraZeneca vaccine, because there is no globally recognized method for measuring GMTs or an accepted standard for what GMT level indicates effective protection.
The interim results of the company’s phase 2 clinical trials, released in late June, show that participants in the 19 to 64 age group had a seroconversion rate of 95.65 percent, meaning that 95.65 percent of participants produced neutralizing antibodies.
At the time, the company said that the GMT level was 102.3, while the GMT level of the AstraZeneca vaccine was 187.9, according to the FDA.
The comany had said that it would continue its phase 2 clinical trials in Taiwan and that its parent company, United Biomedical Inc, would re-evaluate the benefits of conducting phase 3 clinical trials.
At Sunday’s news conference, Wang did not say whether the company was proceeding with its plan to begin phase 2/3 efficacy trials in India, which were expected to have 11,000 participants.
The company would conduct phase 3 clinical trials in India for its “next-generation” COVID-19 vaccine, named “UB-613,” she said, without elaborating.
Apple Inc has closed in on an agreement with OpenAI to use the start-up’s technology on the iPhone, part of a broader push to bring artificial intelligence (AI) features to its devices, people familiar with the matter said. The two sides have been finalizing terms for a pact to use ChatGPT features in Apple’s iOS 18, the next iPhone operating system, said the people, who asked not to be identified because the situation is private. Apple also has held talks with Alphabet Inc’s Google about licensing its Gemini chatbot. Those discussions have not led to an agreement, but are ongoing. An OpenAI
INSATIABLE: Almost all AI innovators are working with the chipmaker to address the rapidly growing AI-related demand for energy-efficient computing power, the CEO said Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) yesterday reported about 60 percent annual growth in revenue for last month, benefiting from rapidly growing demand for artificial intelligence (AI) and high-performance computing applications. Revenue last month expanded to NT$236.02 billion (US$7.28 billion), compared with NT$147.9 billion in April last year, the second-highest level in company history, TSMC said in a statement. On a monthly basis, revenue surged 20.9 percent, from NT$195.21 billion in March. As AI-related applications continue to show strong growth, TSMC expects revenue to expand about 27.6 percent year-on-year during the current quarter to between US$19.6 billion and US$20.4 billion. That would
Apple Inc has been developing a homegrown chip to run artificial intelligence (AI) tools in data centers, although it is unclear if the semiconductor would ever be deployed, the Wall Street Journal reported on Monday. The effort would build on Apple’s previous efforts to make in-house chips, which run in its iPhones, Macs and other devices, according to the Journal, which cited unidentified people familiar with the matter. The server project is code-named ACDC (Apple Chips in Data Center) within the company, aiming to utilize Apple’s expertise in chip design for the company’s server infrastructure, the newspaper said. While this initiative has been
‘FULL SUPPORT’: Kumamoto Governor Takashi Kimura said he hopes more companies would settle in the prefecture to create an area similar to Taiwan’s Hsinchu Science Park The newly elected governor of Japan’s Kumamoto Prefecture said he is ready to ensure wide-ranging support to woo Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) to build its third Japanese chip factory there. Concerns of groundwater shortages when TSMC’s two plants begin operations in the prefecture’s Kikuyo have spurred discussions about the possibility of tapping unused dam water, Kumamoto Governor Takashi Kimura said in an interview on Saturday. While Kimura said talks about a third plant have yet to occur, Bloomberg had reported TSMC is already considering its third Japanese fab — also in Kumamoto — which would make more advanced chips. “We are